Syros Pharmaceuticals Inc (NASDAQ:SYRS)’s share price shot up 12.7% during trading on Wednesday . The company traded as high as $10.61 and last traded at $9.52. 2,054,600 shares changed hands during trading, an increase of 1,474% from the average session volume of 130,539 shares. The stock had previously closed at $8.45.

Several research firms recently weighed in on SYRS. Piper Jaffray Companies restated an “overweight” rating and set a $30.00 target price on shares of Syros Pharmaceuticals in a research note on Tuesday, October 31st. Oppenheimer restated a “buy” rating and set a $28.00 target price on shares of Syros Pharmaceuticals in a research note on Thursday, December 7th. Zacks Investment Research cut Syros Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, October 11th. Roth Capital began coverage on Syros Pharmaceuticals in a research note on Monday, October 23rd. They set a “neutral” rating and a $15.00 target price for the company. Finally, ValuEngine cut Syros Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, September 22nd. One research analyst has rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the company. Syros Pharmaceuticals presently has an average rating of “Buy” and an average target price of $26.14.

Syros Pharmaceuticals (NASDAQ:SYRS) last issued its quarterly earnings data on Wednesday, November 8th. The company reported ($0.53) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($0.53). equities analysts anticipate that Syros Pharmaceuticals Inc will post -2.1 earnings per share for the current fiscal year.

In other news, Director Srinivas Akkaraju acquired 109,774 shares of Syros Pharmaceuticals stock in a transaction on Thursday, December 14th. The stock was bought at an average price of $9.03 per share, for a total transaction of $991,259.22. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 33.60% of the stock is currently owned by insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of SYRS. FMR LLC raised its stake in shares of Syros Pharmaceuticals by 11.9% during the second quarter. FMR LLC now owns 3,926,998 shares of the company’s stock worth $63,185,000 after purchasing an additional 418,061 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Syros Pharmaceuticals by 189.6% during the second quarter. Vanguard Group Inc. now owns 382,603 shares of the company’s stock worth $6,156,000 after purchasing an additional 250,507 shares during the last quarter. Candriam Luxembourg S.C.A. purchased a new stake in shares of Syros Pharmaceuticals during the third quarter worth approximately $1,766,000. State Street Corp raised its stake in shares of Syros Pharmaceuticals by 176.7% during the second quarter. State Street Corp now owns 169,497 shares of the company’s stock worth $2,728,000 after purchasing an additional 108,250 shares during the last quarter. Finally, AWM Investment Company Inc. raised its stake in shares of Syros Pharmaceuticals by 155.8% during the second quarter. AWM Investment Company Inc. now owns 121,624 shares of the company’s stock worth $1,957,000 after purchasing an additional 74,074 shares during the last quarter. Institutional investors own 58.02% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This article was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this article on another domain, it was copied illegally and republished in violation of international trademark & copyright legislation. The original version of this article can be accessed at https://www.thecerbatgem.com/2017/12/15/syros-pharmaceuticals-syrs-trading-12-7-higher.html.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.

Receive News & Stock Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related stocks with our FREE daily email newsletter.